Approximately 18.1% reported treatment-emergent adverse events (TEAEs), with the most frequently reported being nasopharyngitis (2.6%) and upper respiratory tract infection (1.3%), as per a 26 March media release.
The two vehicle-controlled, 12-week Phase III Winlevi trials—708-patient Study 25 (NCT02608450) and 732-patient Study 26 (NCT02608476)—have the same coprimary endpoints, with one being a two-point reduction and Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). This endpoint was achieved by 16.1% of Winlevi intention-to-treat (ITT) patients versus 7% vehicle-only patients (p=0.0012) in Study 25. In Study 26, this was 18.7% in Winlevi ITT patients and 4.7% with vehicle-only patients (p<0.0001), as per a July 2018 media release.
Above is the Winlevi data. I don't think its too late as long it can it have similar efficaciousness and less adverse events. Plus CBD is more marketable.
- Forums
- ASX - By Stock
- Ann: BTX 1801 Phase 2a Antimicrobial Study Underway
Approximately 18.1% reported treatment-emergent adverse events...
-
- There are more pages in this discussion • 229 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $615.4M |
Open | High | Low | Value | Volume |
32.0¢ | 34.0¢ | 32.0¢ | $1.776M | 5.339M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 118187 | 33.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.0¢ | 698385 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 118187 | 0.335 |
5 | 47944 | 0.330 |
10 | 655576 | 0.325 |
24 | 1211890 | 0.320 |
12 | 845958 | 0.315 |
Price($) | Vol. | No. |
---|---|---|
0.340 | 698385 | 8 |
0.345 | 214401 | 6 |
0.350 | 265310 | 8 |
0.355 | 133069 | 6 |
0.360 | 429541 | 11 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |